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Background: The feasibility of introducing three separate Cepheid GeneXpert assays
was assessed: Xpert SA Nasal Complete, Xpert C. difficile, and Xpert Norovirus for point-
of-care testing (POCT) on a ward in a district general hospital.
Aim: To establish a seven-day/24 h POCT service for meticillin-resistant Staphylococcus
aureus (MRSA), Clostridioides difficile, and norovirus operated solely by healthcare
workers (HCWs).
Methods: The Cepheid GeneXpert assays performance characteristics were assessed by
comparing the assays to traditional central laboratory methods in terms of clinical turn-
around times, hands-on time, number of process steps, time to result and diagnostic
accuracy. HCW feedback was collected to consider the potential added value of applying
this technology to improve patient flow and clinical care.
Findings: In total 1170 tests were carried out over the 16-month study period. The assays
significantly reduced hands-on time, process steps, and time to result for identification of
all three micro-organisms. Overall agreement with central laboratory testing was >98% for
all three assays. Staff members fed back that POCT had a positive impact in terms of
clinical utility.
Conclusion: Xpert SA Nasal Complete for MRSA detection, Xpert C. difficile, and Xpert
Norovirus can be used as POCT solely by HCWs in a ward setting. Each assay was used
throughout a seven-day/24 h period with potential positive impact on bed management
and patient care.
Crown Copyright ª 2019 Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. All rights reserved.crobiology, NHS Lothian,
e Crescent, Old Dalkeith
131 536 1000.
ewar).
by Elsevier Ltd on behalf ofIntroduction
Microbiology and virology diagnostic services play a key role
informing infection prevention and control (IPC) strategies,
antimicrobial stewardship, and clinical management. It has
been estimated that diagnostic services support 80% of allThe Healthcare Infection Society. All rights reserved.
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sample results are essential in order for this to occur. Tradi-
tional microbiology, however, is often culture-based and
reportable results can sometimes take days to deliver [2].
Additionally there is a sustainability challenge in microbiology
services due to reduced staffing, increasing costs, greater
demand for services and a rising ageing population [3,4].
Centralization of laboratory services in some instances has
been introduced to address these issues. However, concern has
been reported that sample turnaround times may increase, due
to batch processing of clinical specimens and the distance from
patient care to laboratories increasing (increased specimen
transport time) [5]. It has been reported however that good
transport links and extended shift working in some centres can
overcome these issues [4]. As clinical microbiology has entered
a new era of molecular diagnostics, rapid point-of-care tests
(POCTs) could be an alternative option to resolving some of
these challenges. POCTs have been introduced to detect a
number of pathogens such as human immunodeficiency virus
(HIV), respiratory syncytial virus (RSV), influenza, group A
streptococcus, and dengue [6]. The rapid turnaround times of
POCTs are potentially beneficial for making decisions in a
variety of clinical situations including antimicrobial steward-
ship and IPC strategies. Indeed a systematic review published
in 2013 identified that POCTs for RSV and norovirus had the
greatest impact upon IPC measures; however, at that time,
issues still remained regarding test sensitivity, staff training,
and the high costs of the tests [7]. The objective of this current
study was to determine the feasibility of establishing a
healthcare worker (HCW)-controlled POCT service for the
detection of meticillin-resistant Staphylococcus aureus
(MRSA), Clostridioides difficile, and norovirus using multiple
separate assays on a rural district general hospital: Dr Gray’s
Hospital Elgin is 65 miles (90 min travelling time) from the
microbiology/virology laboratory facilities provided at Aber-
deen Royal Infirmary. The performance of each POCT assay was
compared to baseline routine microbiology testing data in
terms of hands-on time, number of process steps, time to result
and diagnostic accuracy. A staff questionnaire was also used to
gauge opinion on perceived benefits and acceptability of pol-
ymerase chain reaction (PCR)-POCTs.Methods
Study design and microbiology methods
POCTs were performed in Dr Gray’s Hospital, Elgin, which is
a rural district general hospital in Scotland with 210 staffed
beds, and no microbiology or virology laboratory facilities on
site. A Cepheid GeneXpert Rapid Molecular Diagnostic Plat-
form (Cepheid, Sunnyvale, CA, USA) (Supplementary Figure S1)
was situated on the stroke ward which has eight beds. This
HCW-operated POCT evaluation study ran prospectively from
October 16th, 2014 to January 18th, 2016. In total, 26 non-
laboratory staff were trained to use the GeneXpert (health-
care assistants and qualified nursing staff). All staff received
training from the company. Patient specimens, including nasal
swabs (Copan, Brescia, Italy) for MRSA screening and faeces for
norovirus and/or C. difficile testing, were routinely taken as
part of patient care on Dr Gray’s hospital wards and were
transported to the Stroke ward by healthcare support workers.The following assays were used as per manufacturer’s
instructions: Xpert SA Nasal Complete for MRSA testing, Xpert
C. difficile and Xpert Norovirus on the Cepheid GeneXpert
rapid molecular diagnostic platform [8e10]. Xpert SA Nasal
Complete detects sequences for the staphylococcal protein A
(spa), the gene for meticillin/oxacillin resistance (mecA), and
the staphylococcal cassette chromosome (SCCmec) inserted
into the SA chromosomal attB site [8]. Xpert C. difficile detects
sequences of the genes for toxin B (tcdB), binary toxin (cdt),
and a point mutation associated with ribotype 027 [9]. A pos-
itive test for the toxin B target indicates that toxogenic
C. difficle has been detected; the other two targets provide
information about the presence of presumptive ribotype 027.
Xpert Norovirus detects sequences for norovirus genotype I and
genotype II [10]. The automated system consisted of an
instrument, personal computer, and preloaded software for
running tests and viewing the results. The system requires
single-use disposable cartridges that hold the PCR reagents and
host the PCR process. The assays contain a sample processing
control (SPC) for adequate processing of the target bacteria
and to monitor the presence of inhibitor(s) in the PCR reaction.
Probe check control confirms dye stability, reagent rehydra-
tion, PCR tube filling in the cartridge and probe integrity.
Results were reported as ‘positive’, ‘negative’, ‘invalid’,
‘error’, or ‘no result’. ‘Invalid’ results could be due to failure of
the SPC, PCR inhibition, or problems with the sample not being
properly processed. ‘Error’ results indicated that there had
been: a probe check control failure and the assay was aborted
potentially due to improper filling of the reaction tube; reagent
probe integrity problem; maximum pressure limits had been
exceeded; or valve positioning error was detected. A ‘no
result’ indicated that insufficient data had been collected, for
instance, an operator had stopped a test that had been in
progress [9]. The Cepheid testing was performed by an HCW
and a preliminary result placed in the patient medical notes.
Patient specimens were sent to the central laboratory at
Aberdeen Royal Infirmary for routine microbiology testing.
The Infirmary has 900 staffed beds and complete range of
medical and clinical specialties. Transport was by road,
twice daily from Monday to Friday and once on Saturday
(there was no routine sample transport on Sunday). Speci-
mens were transported to Aberdeen at ambient temper-
ature, where they were refrigerated upon arrival until
processing by traditional microbiology methods seven days
per week. For MRSA testing, nasal swabs were cultured on
BrillianceTM MRSA Agar (Oxoid Ltd, Basingstoke, UK) and the
coagulase test was carried out on isolated organisms using
ProlexTM Staph Xtra Latex kit (Pro-Lab Diagnostics, Brom-
borough, UK). Formal bacterial identification was performed
on the Vitek MS (bioMerieux, Marcy l’Etoile, France) and
antibiotic sensitivity carried out by Vitek 2 (bioMérieux).
Enzyme immunoassay (EIA) for glutamate dehydrogenase
(GDH) followed by toxin testing (Meridian Bioscience, Cin-
cinnati, OH, USA) was used for identification of C. difficile
on faeces specimens as per national guidance [11].
C. difficile PCR was not used by the central laboratory as
part of its C. difficile diagnostic tests and so direct comparison
of POCT-PCR with an equivocal PCR method could not be
undertaken. Laboratory detection of norovirus RNA (norovirus
genotype I and genotype II) in patient faeces was carried out by
TaqMan real-time reverse-transcriptase PCR as previously
described [12,13].
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Cepheid assay results and traditional testing information
were collected from the Cepheid GeneXpert rapid molecular
diagnostic platform and laboratory information management
system (LIMS) respectively. As part of this, two sets of data were
collected, the first involving 12 months of baseline data
reflecting pre-existing testing methods from 2013 to 2014, the
second including test phase evaluation data collected for the
duration of the POCT during 2014e2016. Baseline and evalua-
tion data were directly compared. Data included sample col-
lection date/time; date/time samples were received in the
laboratory, patient location code, ward, test start date, test
start time, final results, report date and time to identify the
clinical turnaround times (CTATs), i.e. time from sample taken
to report available to the clinician. Clinical and laboratory data
were analysed in Microsoft Excel. Standard formulae were
used to calculate the sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) with 95% con-
fidence interval (CI) [14]. HCW feedback was gained at the
end of the study to inform acceptability, bed management,
and patient care. Caldicott guardian approval was gained from
NHS Grampian in order to enable appropriate information
sharing and to protect the confidentiality of patients, and the
study was approved by the Clinical Effectiveness Unit in NHS
Grampian.Results
Overall 1170 samples underwent Cepheid GeneXpert assay
testing. Figure 1 demonstrates the number of results which
were reported as ‘positive’, ‘negative’, ‘invalid’, ‘no result’ or
‘error’. There was a significant reduction in CTATs from base-
line (before PCR-POCT) to test phase (introduction of PCR-
POCT) for all three organisms. For MRSA the median CTATs
for traditional methods was 44 h compared to 3 h for POCT (P<
0.05), for C. difficilemedian CTATs for traditional methods was
84 h compared to 3 h for POCT (P < 0.05), and for norovirus
median CTATs for traditional methods was 54 h compared to 3 h
for POCT (P < 0.05) (Supplementary Figure S2). Each assay
greatly reduced hands-on time, number of process steps, and
time to result (Table I). Analysis of the Cepheid GeneXpert
rapid molecular diagnostic platform user data identified that
specimens were tested over a 24 h period for all assays
(Supplementary Figures S3eS5).Xpert SA Nasal Complete
In total, 688 POCTs for MRSA detection were completed
during the evaluation period, of which 605 had concomitant
bacterial culture (see Figure 1 for exclusions). The Cepheid was
positive in 17 samples; 10 were culture positive (true positive)
and seven culture negative. CT values for the seven false-
positive Cepheid samples are shown in Supplementary
Table S1. Overall in 598 out of 605 samples (98.8%) there was
concordance with the central laboratory result. Xpert SA Nasal
Complete sensitivity for MRSA was found to be 100% (95% con-
fidence interval (CI): 65.55e100), specificity 98.82% (95% CI:
97.48e99.48), PPV 58.82% (95% CI: 33.45e80.57) and NPV 100%
(95% CI: 99.19e100) compared with reference standard MRSA
detention by culture methods.Xpert C. difficile
In all, 257 POCTs were carried out using the Xpert C. difficile
assay, of which 195 had a concomitant GDH test (see Figure 1
for exclusions; note that in the initial stage of the evaluation
the laboratory had not yet implemented C. difficile testing as
per national guidance and that 30 specimens were tested by
methods other than GDH). In total there were 170 specimens
tested which were negative by GDH and Xpert C. difficile
(Xpert C. difficile true negative). Seventeen samples were
positive by POCT-PCR and laboratory GDH. There were six
instances in which Xpert C. difficile was negative yet the
specimen was positive by GDH, which may be explained by the
presence of non-toxigenic C. difficile. There were two cases in
which the Xpert C. difficile was positive, but laboratory-based
GDH negative (considered discrepant). Overall agreement was
99.0%.
Xpert Norovirus assay, of which 155 had a concomitant
norovirus laboratory PCR
In total 225 POCTs were completed during this evaluation
period using the Xpert Norovirus, of which 155 had a con-
comitant norovirus laboratory PCR (see Figure 1 for exclusions).
Xpert Norovirus was positive in seven cases; five were con-
firmed by laboratory PCR (Xpert Norovirus true positives)
and two were negative by laboratory PCR (Xpert Norovirus
false positives). Xpert Norovirus was negative in 148 cases; 147
were negative by laboratory PCR (Xpert Norovirus true neg-
ative) and one case was positive by laboratory PCR (Xpert
Norovirus false negative). Overall in 152 out of 155 samples
(98.1%) there was concordance with the central laboratory
result. Xpert Norovirus sensitivity was 83.33% (95% CI:
36.48e99.12), sensitivity 98.66% (95% CI: 94.74e99.77), PPV
71.43% (95% CI: 30.26e94.89) and NPV 99.32% (95% CI:
95.73e99.96) compared to reference-standard detection by
laboratory PCR method.
Evaluation of HCWs’ perceptions
Eleven members of staff who regularly operated the Gene-
Expert gave feedback on their experiences. They responded to
a series of statements (Table II). HCWs rated their answers
from 1 (strongly disagree) to 5 (strongly agree). Overall staff
reported that the tests were easy to perform, giving faster
results. They identified that, out of the three Cepheid Gene-
Expert assays, the use of Xpert Norovirus was most favourable
in improved bed management whereas the use of Xpert SA
Nasal Complete was most favourable in improved patient care.
Discussion
This study provides evidence that rural hospitals without
microbiology or virology laboratories can improve their CTATs
for MRSA, C. difficile, and norovirus by using POCT methods.
One strength of the study is that testing was solely conducted
by HCWs rather than by laboratory-trained staff, as has been
the case in previous studies [15,16]. The most common test
carried out was SA Nasal Complete, which had a sensitivity of
100.00% for MRSA detection, similar to findings from previously
reported POCT studies [17e21]. The PPV in our study was low
Overall 1170 samples tested by Xpert SA 
Nasal Complete (for MRSA detection), Xpert
C. difficile and Xpert Norovirus
225 samples tested for 
Norovirus by Xpert
Norovirus. 4 errors. 2 no result. 34 invalid (15.11%). 30 not sent/rejected
257 samples tested for C. 
difficile by Xpert C.
difficile. 8 errors. 1 no result. 6 invalid (2.33%). 17 not sent/rejected. 30 not tested by GDH
688 samples tested for 
MRSA by Xpert SA
Nasal Complete. 5 errors. 6 no result. 56 invalid (8.14%). 16 not sent/rejected
195 samples with GDH. 170 GDH 
negative/Xpert C.
difficile negative . 17 GDH positive/Xpert
C. difficile positive. 2 GDH negative/Xpert
C. difficile positive. 6 GDH positive/Xpert
C. difficile negative 
605 samples with 
bacterial culture. 588 culture 
negative/Xpert SA Nasal 
Complete negative 
(Xpert SA Nasal 
Complete true negative). 10 culture positive/Xpert 
SA Nasal Complete 
positive (Xpert SA 
Nasal Complete true 
positive). 7 culture 
negatives/Xpert SA 
Nasal Complete positive 
(Xpert SA Nasal 
Complete false positive). 0 culture positive/Xpert 
SA Nasal Complete 
negative (Xpert SA 
Nasal Complete false 
negative)
155 samples with 
laboratory PCR. 147 laboratory PCR 
negative/Xpert 
Norovirus negative
(Xpert Norovirus true 
negative). 5 laboratory PCR 
positive/Xpert 
Norovirus positive 
(Xpert Norovirus true 
positive). 2 laboratory PCR 
negative/Xpert 
Norovirus positive
(Xpert Norovirus false 
positive). 1 laboratory PCR 
positive/Xpert 
Norovirus negative 
(Xpert Norovirus false 
negative)
Figure 1. Results of Xpert SA Nasal Complete, Xpert C. difficile, and Xpert Norovirus Tests and central laboratory tests performed. MRSA,
meticillin-resistant Staphylococcus aureus; GDH, glutamate dehydrogenase; PCR, polymerase chain reaction.
S. Dewar et al. / Journal of Hospital Infection 103 (2019) 447e453450(58.82%) and may reflect the low prevalence of MRSA in the
patient population tested. Discordant screening tests have
been described before, and, although we did not detect any
false-negative PCR results, we did identify seven patients with
positive MRSA results on the Cepheid SA Nasal Complete which
were subsequently culture negative by traditional methods.
This could be explained by the following: low-level colo-
nization, antibiotic use, opsonizing antibody to S. aureus, poor
sampling, or non-viable organisms from the specimen [18]. In aprevious study, in POCT-positive/culture-negative MRSA cases
there was no evidence of MRSA infection or colonization in
these patients for a year post procedure [20]. Potential unin-
tentional consequences of false-positive MRSA identification
include inappropriate isolation, decolonization, and potential
prescriptions of anti-MRSA-targeted antimicrobials.
The Xpert Norovirus proportionately had the most con-
firmatory samples that were not sent or rejected by the lab-
oratory. It also had the highest proportion of invalid results
Table I





















MRSA Xpert SA Nasal
Complete
0:00:30 11 1:07:00 Culture 0:06:30 30 24:00:00
C. difficile Xpert C. difficile 0:00:30 11 1:04:00 GDH/toxin 0:48:00 106 4:08:00
Norovirus Xpert Norovirus 0:00:30 11 1:04:00 Laboratory PCR 0:0:30 17 3:12:00
MRSA, meticillin-resistant Staphylococcus aureus; GDH, glutamate dehydrogenase; PCR, polymerase chain reaction.
Table II
Average scores of healthcare worker feedback on use of Xpert SA Nasal Complete, Xpert C. difficile, and Xpert Norovirus assays and impact
on clinical utility
Statement Xpert SA Nasal Complete Xpert C. difficile Xpert Norovirus
The test was easy to perform 4.50 4.36 4.22
The technology means I am more likely to send specimens 3.88 3.27 3.50
I like the idea of carrying out the test on the ward 3.88 3.73 3.44
I like the idea of carrying out the test myself 3.88 3.82 3.44
Testing is an acceptable part of my job 3.75 3.64 3.44
The technology gives me faster results 4.62 4.80 4.78
The technology improves bed management 3.75 4.22 4.25
The technology improves patient care 4.40 3.67 3.67
Healthcare workers rated their answers from 1 (strongly disagree) to 5 (strongly agree).
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results occur when the sample is not properly processed, PCR
is inhibited, or the sample is not properly collected (e.g. too
much stool in the sample can often result in invalid results)
[10]. Moreover, the fact that users found this Xpert Norovirus
the least easy to perform may have resulted in improper
processing and a high proportion of invalid results. The sen-
sitivity of the Xpert Norovirus was 83.33% and PPV 71.43%,
lower values than previously reported [22,23]. There is no
established reference-standard nucleic acid amplification
test (NAAT) for norovirus testing and the variation in Xpert
Norovirus performance may reflect the different comparator
laboratory PCR used in these studies. Interestingly authors
from a previous study concluded that the POCT Xpert Noro-
virus assay in their hands may have been more reliable than
laboratory PCR in detecting norovirus [23]. They therefore
proposed that caution should be taken when using laboratory
PCR as a comparator.
The optimal laboratory diagnosis for C. difficile infection
has been an area of controversy for many years. Direct cell
cytotoxicity assay and toxigenic culture were the first two
diagnostic C. difficile tests available, but a major drawback
with these methods is the long turnaround times. EIAs with
rapid turnaround time followed and were developed to detect
toxins and GDH or a combination of these [24,25]. In the last 20
years advances in molecular methods for C. difficile diagnosis
have been made. Various companies have developed auto-
mated and semi-automated NAATs that use PCR or loop-
mediated isothermal amplification of DNA for testing
C. difficile in stool, a significant number of which have been
approved by the US Food and Drug Administration [26]. NAAT or
PCR testing is less common in the UK for C. difficile screening.
The comparator screening test used for C. difficile in this studywas GDH by EIA, which the laboratory adopted at the initial
stages of the evaluation.
A limitation of our study is that we did not directly compare
this assay to another equivalent PCR method to detect
C. difficile. However, the UK national guidance does advise
that C. difficile diagnosis should be based on using GDH EIA or
NAAT to screen samples [11]. A molecular diagnosis of
C. difficile will require confirmation with a sensitive toxin EIA
test (or a cytotoxin assay) as molecular testing for C. difficile
only detects genes associated with toxigenic C. difficile. As a
proof-of-concept study we have shown that POCT-PCR, used
solely by HCWs, could be used as an alternative screening test
to laboratory GDH for C. difficile detection. A recent feasibility
study focusing on the assessment of Cepheid GeneXpert for
diagnosis of C. difficile on three wards and two intensive care
units (ICUs) in a city hospital operated by laboratory techni-
cians found an overall agreement with central laboratory
testing to be 98.1% and the median turnaround time was 1.85 h
for Xpert C. difficile results compared to 18 h for the central
laboratory test [16]. Likewise our study showed good agree-
ment with laboratory testing (99.0% agreement) and the use of
Xpert C. difficile assay reduced CTATs; in our case the median
CTAT for C. difficile detection using traditional methods (GDH
and toxin) was 84 h and this decreased to 3 h using POCT-PR (P
< 0.05). Faster CTATs are also reported in our HCW feedback.
In general, staff who gave feedback on their experience of
using POCT were receptive to this technology and responded
that it allowed for more effective bed management and
improved patient care. This supports previous reports that
when a patient’s sample has undergone POCTs the patient is
three times more likely to be immediately discharged com-
pared to patients who only had their samples tested by tradi-
tional microbiology methods [15]. The use of POCTs has the
S. Dewar et al. / Journal of Hospital Infection 103 (2019) 447e453452potential to meet healthcare deliverables such as streamlining
of health technology, equity of access, sustainability, reducing
antibiotic prescribing, and achieving quality overall in health-
care [27e29]. At the time of the evaluation only two Scottish
microbiology laboratories offered a seven-day/24 h service and
we have shown that POCT can be used to assist in delivering
results for MRSA, C. difficile, and norovirus in a hospital that
does not have onsite testing facilities. If the POCT technology
were to be rolled out routinely we would advise that it would
need to be sustained with increased resource for staff and IT
systems. In our study the GeneXpert system was not interfaced
to LIMS and therefore Cepheid tests could not be ordered from
the LIMS and results could not be transferred electronically to
this system. GeneXpert results were also not transferred to
other systems such as bed management systems and IPC sys-
tems such as ICNet. With the threat of antimicrobial resistance
there are also calls for novel approaches to be undertaken in
terms of new diagnostics with recommendations for invest-
ment in POCTs to assess the appropriateness of diagnosis and
treatment [30]. It is outwith the scope of the study to under-
take a formal cost-benefit/effectiveness study. Consumable
costs per test for rapid, molecular technology are high relative
to traditional methods; however, the associated benefits can
only be appreciated when a whole-hospital approach is taken
(including benefits such as reduced turnaround times,
improved bed-days, reduced transport costs, etc.). Indeed
POCTs may be of greatest value in hospitals with no micro-
biology/virology diagnostic services on site, as outlined in this
study. With this in mind and considering low sensitivity and
delayed results of traditional culturing, it is paramount that we
continually develop and make use of the rapidly emerging
technological advances in the field of real-time diagnostics in
order to deliver the very best standards of healthcare.Acknowledgements
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